. Author manuscript; available in PMC: 2013 Nov 4.

Published in final edited form as: J Natl Med Assoc. 2008 Dec;100(12):1417–1424. doi: 10.1016/s0027-9684(15)31541-8

Table 2.

Multivariable logistic regression model results for the total study cohort and by qualifying drug

Covariate	Total Cohort Model (n=3,654)	PI Model (n=2,757)	NNRTI Model (n=897)

	OR (95% CI); P value	OR (95% CI); P value	OR (95% CI); P value
Race (Black vs. White)	1.54 (1.32–1.79); <0.001	1.55 (1.30–1.85); <0.001	1.46 (1.08–1.99); 0.015
Sex (Female vs. Male)	1.45 (1.23–1.70); <0.001	1.54 (1.28–1.86); <0.001	1.20 (0.87–1.64); 0.26
Age (Per Year Increase)	0.98 (0.97–0.99); <0.001	0.98 (0.97–0.99); <0.001	0.97 (0.95–0.98); <0.001
TennCare Enrollment Criteria (Disabled vs. Other^a)	1.26 (1.08–1.46); 0.003	1.14 (0.96–1.35); 0.14	1.73 (1.28–2.34); <0.001
Early Medical Encounter^b (Yes vs. No)	1.05 (0.88–1.25); 0.59	0.97 (0.79–1.19); 0.78	1.32 (0.94–1.86); 0.11
Qualifying Drug (PI vs. NNRTI)	0.94 (0.80–1.11); 0.45	–	–
Urban Residence^c (Yes vs. No)	0.97 (0.78–1.22); 0.82	0.95 (0.73–1.23); 0.68	1.06 (0.70–1.60); 0.80

OR: Odds ratio; CI: Confidence interval; PI: Protease inhibitor; NNRTI: Non-nucleoside reverse transcriptase inhibitor;

Other includes uninsured status, aid to families of dependent children, qualified Medicare beneficiary and aged;

Defined as an outpatient visit with an HIV-related billing code within 90 days of qualifying drug prescription.